Ovid Therapeutics Inc.
OVID · XNASCIK 1636651fmd_098YX8WY9Z5HMF20K884W8BBCNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2026, 44 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 13 | 208 | 2 | 0 | 1 | 7 |
| Research and development | 10 | 50 | 34 | 42 | 63 | 47 | 25 | 29 | 37 | 26 |
| Total operating expenses | 23 | 65 | 53 | 61 | 94 | 84 | 57 | 60 | 62 | 50 |
| Operating income | (23) | (65) | (53) | (61) | (81) | 124 | (56) | (59) | (62) | (42) |
| Interest and investment income | – | – | – | – | – | – | – | 5 | 4 | 2 |
| Other non-operating income (expense) | 0 | 0 | 1 | 1 | – | (0) | 1 | 7 | 35 | 25 |
| Income before taxes | – | – | – | – | (81) | 124 | (54) | (52) | (26) | (17) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (81) | 123 | (54) | (52) | (26) | (17) |
| Net income | (22) | (65) | (52) | (60) | (81) | 123 | (54) | (52) | (26) | (17) |
| Net income to common shareholders | (22) | (65) | (52) | (60) | (81) | 120 | (54) | (51) | (26) | (17) |